MINERALYS THERAPEUTICS financial statements

미네랄리스 테라퓨틱스NASDAQ:MLYS · Nasdaq · Healthcare
$22.09+0.64%
2026-10-07 close

MINERALYS THERAPEUTICS's published financial data is dated 2026-10-04. 2024 revenue was $0M. 2024 operating profit was −$192M.

Reported results

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 8.72
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
8.72
Beneish M-Score
—

Statistical flag unavailable

Sloan accrual
-5.58%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

MINERALYS THERAPEUTICS notifications

Quantus Signal · live data · not investment advice · Privacy Policy